Incyte officer Pablo J. Cagnoni sells 2,642 shares

Q: How many INCY shares did Pablo J. Cagnoni sell, and at what price?

Pablo J. Cagnoni reported selling 2,642 INCY common shares at $112.71 per share on October 15, 2026. The reported transactions were made pursuant to a Rule 10b5-1 plan.

For the 839-share option lot, options become exercisable in 37 installments beginning January 17, 2025, with the first 25% vesting on July 15, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Incyte Corp (INCY) officer Pablo J. Cagnoni, President, Global Head of R&D, exercised employee stock options on October 15, 2026, for four lots: 839 shares at $71.93, 423 at $61.76, 455 at $61.18 and 925 at $64.25 per share. He also reported selling 2,642 common shares at $112.71 per share. The reported transactions were made pursuant to a Rule 10b5-1 plan.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,642 shares ($124K approx. pre-tax spread)

Exercise and Sale 9 txns

Insider CAGNONI PABLO J

Role President, Global Head of R&D

Sold 2,642 shs ($298K)

Approx. gross sale proceeds $298K

Approx. exercise cost $174K

Approx. pre-tax spread $124K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy) ^F2	839	$0.00	$0.00
Exercise	Employee Stock Option (right to buy) ^F3	423	$0.00	$0.00
Exercise	Employee Stock Option (right to buy) ^F4	455	$0.00	$0.00
Exercise	Employee Stock Option (right to buy) ^F5	925	$0.00	$0.00
Exercise	Common Stock	839	$71.93	$60K
Exercise	Common Stock	423	$61.76	$26K
Exercise	Common Stock	455	$61.18	$28K
Exercise	Common Stock	925	$64.25	$59K
Sale	Common Stock ^F1	2,642	$112.71	$298K

Holdings After Transaction: Employee Stock Option (right to buy) — 44,956 contracts (Direct); Common Stock — 183,200 shares (Direct)

Footnotes (5)

F1. This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
F2. Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.
F3. The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
F4. Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years.
F5. The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Key Figures

Option exercise lot: 839 options; exercise price $71.93 per share Option exercise lot: 423 options; exercise price $61.76 per share Option exercise lot: 455 options; exercise price $61.18 per share +3 more

6 metrics

Option exercise lot 839 options; exercise price $71.93 per share October 15, 2026

Option exercise lot 423 options; exercise price $61.76 per share October 15, 2026

Option exercise lot 455 options; exercise price $61.18 per share October 15, 2026

Option exercise lot 925 options; exercise price $64.25 per share October 15, 2026

Common shares sold 2,642 shares October 15, 2026

Sale price $112.71 per share October 15, 2026

Key Terms

Employee Stock Option (right to buy), restricted stock units, earned performance stock units

3 terms

Employee Stock Option (right to buy) technical

"Employee Stock Option (right to buy)"

restricted stock units technical

"previously reported restricted stock units and earned performance stock units that have not vested"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

earned performance stock units technical

"previously reported restricted stock units and earned performance stock units that have not vested"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many INCY shares did Pablo J. Cagnoni sell, and at what price?

Pablo J. Cagnoni reported selling 2,642 INCY common shares at $112.71 per share on October 15, 2026. The reported transactions were made pursuant to a Rule 10b5-1 plan.

What INCY options did Pablo J. Cagnoni exercise?

On October 15, 2026, Pablo J. Cagnoni exercised options for 839 shares at $71.93, 423 at $61.76, 455 at $61.18 and 925 at $64.25 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/19/2026 - 04:38 PM EDT Accepted by SEC EDGAR 10/19/2026 - 04:38 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAGNONI PABLO J

(Last)

(First)

(Middle)

1801 AUGUSTINE CUT-OFF

(Street)

WILMINGTON

DELAWARE

19803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, Global Head of R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/15/2026		M		839	A	$71.93	184,039	D
Common Stock	10/15/2026		M		423	A	$61.76	184,462	D
Common Stock	10/15/2026		M		455	A	$61.18	184,917	D
Common Stock	10/15/2026		M		925	A	$64.25	185,842	D
Common Stock	10/15/2026		S		2,642	D	$112.71	183,200⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$71.93	10/15/2026		M			839	⁽²⁾	01/16/2035	Common Stock	839	$0	17,627	D
Employee Stock Option (right to buy)	$61.76	10/15/2026		M			423	⁽³⁾	07/13/2033	Common Stock	423	$0	3,802	D
Employee Stock Option (right to buy)	$61.18	10/15/2026		M			455	⁽⁴⁾	01/17/2034	Common Stock	455	$0	4,096	D
Employee Stock Option (right to buy)	$64.25	10/15/2026		M			925	⁽⁵⁾	07/14/2034	Common Stock	925	$0	19,431	D

Explanation of Responses:

1. This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

2. Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

3. The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

4. Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years.

5. The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Remarks:

	/s/ Elizabeth Feeney, Attorney-In-Fact	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR